Phase 3 trial in 1613 adults with type 2 diabetes and BMI ≥27: orforglipron 6, 12 and 36 mg cut bodyweight by 5.1%, 7.0% and 9.6% at 72 weeks vs 2.5% with placebo (all p<0.0001). Discontinuation for adverse events was higher (6.1-9.9% vs 4.1%).
RCTn = 1,613
Horn et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial